BioCentury
ARTICLE | Company News

Pfizer, MD Anderson partner for cancer combo clinical trials

September 29, 2017 9:35 PM UTC

University of Texas MD Anderson Cancer Center (Houston, Texas) partnered with Pfizer Inc. (NYSE:PFE) to identify patients who respond to immunotherapy and evaluate combinations of Pfizer’s immuno-oncology candidates in a series of clinical trials.

MD Anderson will conduct at least five Phase Ib trials in patients with solid tumors and hematologic malignancies. MD Anderson expects the majority of the trials to begin in late 2017...